A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2005

Study Completion Date

April 30, 2007

Conditions

Prostate Cancer

Interventions

DRUG

CC5013

Trial Locations (6)

Roswell Park Cancer Institute, Buffalo

Moffit Cancer Center, Tampa

Alta Bates Cancer Center, Berkeley

Seattle Cancer Care Alliance, Seattle

Dana Farber Cancer Institute, Boston

Cancer Institute of New Jersey, New Brunswick